Sugi Predict

Sugi Predict / Compounds / SCHEMBL3676085

SCHEMBL3676085

SCHEMBL3676085

COCC(O)CC(=O)OC

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.42
▸ HSD17B10 Q99714 1/20 0.39
▸ MGAM O43451 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ SI P14410 1/20 0.39
▸ MGAM2 Q2M2H8 1/20 0.39
▸ MAPT P10636 3/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ TET2 Q6N021 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ CA12 O43570 1/20 0.31
▸ CA14 Q9ULX7 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ RECQL P46063 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3676083 1.00 TSHR (0.42) TSHRHSD17B10MGAMGAASI
SCHEMBL15892737 0.86 TSHR (0.42) TSHRHSD17B10MGAMGAASI
SCHEMBL28243 0.85 TSHR (0.50) TSHRHSD17B10MGAMGAASI
SCHEMBL3932264 0.82 TSHR (0.39) TSHRHSD17B10MGAMGAASI
SCHEMBL3681909 0.80 KDM4E (0.38) TSHRHSD17B10MGAMGAASI
SCHEMBL3681911 0.80 KDM4E (0.38) TSHRHSD17B10MGAMGAASI
SCHEMBL5986514 0.80 KDM4E (0.38) TSHRHSD17B10MGAMGAASI
SCHEMBL3679589 0.80 MGAM (0.44) TSHRHSD17B10MGAMGAASI
SCHEMBL3679588 0.80 MGAM (0.44) TSHRHSD17B10MGAMGAASI
SCHEMBL28845576 0.79 L3MBTL1 (0.39) TSHRHSD17B10MGAMGAASI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4003988-B1 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS SERVIER LAB (FR) 2026-05-20 — — EP disclosed
EP-4501932-A2 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2025-02-05 — — EP disclosed
EP-3880208-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-11-20 — — EP disclosed
CN-111989321-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2024-05-14 — — CN disclosed
US-20240101553-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-03-28 — — US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
EP-3710439-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-02-15 — — EP disclosed
US-20220289734-A1 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS LES LABORATOIRES SERVIER (FR) 2022-09-15 — — US disclosed
EP-4003988-A1 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS Les Laboratoires Servier (FR) 2022-06-01 — — EP disclosed
US-20190270743-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2019-09-05 — — US disclosed
US-20190144444-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2019-05-16 — — US disclosed
EP-1616852-B1 PROCESS FOR PRODUCING BETA-HYDROXYESTER DAISO CO LTD (JP) 2010-08-11 — — EP disclosed
US-7256305-B2 Process for producing β-hydroxyester DAISO CO., LTD. (JP) 2007-08-14 — — US disclosed
US-20060122419-A1 Esterification of an epoxide, an alcohol and carbon monoxide in the presence of a cobalt carbonyl compound as catalyst and a cocatalyst of substituted pyridine DAISO CO., LTD. (JP) 2006-06-08 — — US disclosed
EP-1616852-A1 PROCESS FOR PRODUCING BETA-HYDROXYESTER DAISO CO., LTD. (JP) 2006-01-18 — — EP disclosed
EP-1292555-B1 CATALYTIC HYDROGENATION OF KETONES AND ALDEHYDES DU PONT (US) 2004-03-03 — — EP disclosed
EP-1292555-A2 CATALYTIC HYDROGENATION OF KETONES AND ALDEHYDES E.I. DUPONT DE NEMOURS AND COMPANY (US) 2003-03-19 — — EP disclosed
US-6462206-B1 REDUCING KETONES AND ALDEHYDES TO THE CORRESPONDING ALCOHOL OR ALKYL GROUP, USING H2 GAS AS THE STOICHIOMETRIC REDUCTANT; FORMING CORRESPONDING LACTONES E. I. DU PONT DE NEMOURS AND COMPANY 2002-10-08 — — US disclosed
WO-2001098238-A2 CATALYTIC HYDROGENATION OF KETONES AND ALDEHYDES E.I. DUPONT DE NEMOURS AND COMPANY (US) 2001-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190144444-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TSHR 4273/4885HSD17B10 3889/4885MGAM 3341/4885
US-20060122419-A1 Esterification of an epoxide, an alcohol and carbon monoxide in the presence of a cobalt carbonyl compound as catalyst and a cocatalyst of substituted pyridine CYP2E1, CBR1, ADH1A TSHR 4380/4885HSD17B10 78/4885MGAM 2253/4885
US-20220289734-A1 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS CASP3, BAX, CASP2 TSHR 4066/4885HSD17B10 1273/4885MGAM 4872/4885
US-20240101553-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TSHR 4273/4885HSD17B10 3889/4885MGAM 3341/4885
US-20190270743-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TSHR 4273/4885HSD17B10 3889/4885MGAM 3341/4885
US-20230373999-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TSHR 4273/4885HSD17B10 3889/4885MGAM 3341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.